Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.67 |
| ▸ | RELA | Q04206 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | PNLIP | P16233 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12163171 | 0.86 | KMT2A (0.73) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL18327174 | 0.85 | LMNA (0.89) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL2698820 | 0.84 | RXFP1 (0.62) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL9142328 | 0.83 | NPC1 (0.67) | LMNANPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL8665327 | 0.82 | CA1 (0.74) | HTTNPC1RAB9ASMN1; SMN2MEN1 | |
| Salicylanilide SCHEMBL5801957 | 0.81 | MEN1 (0.96) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL5079177 | 0.80 | RAB9A (1.00) | LMNATP53HTTNPC1RAB9A | |
| Osalmid SCHEMBL220088 | 0.80 | LMNA (1.00) | LMNATP53HTTNPC1RAB9A | |
| Osalmid SCHEMBL29928981 | 0.80 | LMNA (1.00) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL22140120 | 0.80 | AVPR2 (0.73) | LMNAPOLBAVPR2GPR27 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | PYGL, GYS2, GLS2 | LMNA 3131/4885TP53 281/4885HTT 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.